Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

INTRODUCTION: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the interim safety, tolerability, and efficacy of tofacitinib in PsA patients in OPAL Balance, a 3-year, open-label, long-term extension study (data cut-off: August 2017; database no...

Descripción completa

Detalles Bibliográficos
Autores principales: Nash, Peter, Coates, Laura C., Kivitz, Alan J., Mease, Philip J., Gladman, Dafna D., Covarrubias-Cobos, José A., FitzGerald, Oliver, Fleishaker, Dona, Wang, Cunshan, Wu, Joseph, Hsu, Ming-Ann, Menon, Sujatha, Fallon, Lara, Romero, Ana Belén, Kanik, Keith S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410915/
https://www.ncbi.nlm.nih.gov/pubmed/32506317
http://dx.doi.org/10.1007/s40744-020-00209-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410915/
https://www.ncbi.nlm.nih.gov/pubmed/32506317
http://dx.doi.org/10.1007/s40744-020-00209-4

Ejemplares similares